A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers

By Scott L. Carter, A. Eklund, Isaac S. Kohane, L. Harris, Zoltan Szallasi. Nature Genetics, 2006

1,175 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Oncology

View Paper: https://www.semanticscholar.org/paper/80d2059fa4d249a57fec3ee24a5c4d5d46df0a40

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Balázs Győrffy
2. H. Horlings
3. Jacques E. Dumont
4. Matthew Meyerson
5. Marcos Malumbres
6. Vincent Detours
7. David Venet
8. M. Barbacid

In Genetics

1. Jacques E. Dumont
2. Marcos Malumbres
3. S. Taube
4. Vincent Detours
5. David Venet
6. Balázs Győrffy

In Oncology

1. H. Horlings
2. Marcos Malumbres
3. M. Barbacid
4. Larry Norton
5. Balázs Győrffy

Citations in the corpus

• Jetset: selecting the optimal microarray probe set to represent a gene (2011, background): “We previously identified a set of 70 co-expressed genes whose expression is associated with chromosomal instability (CIN) in cancer [21].”
• Genomic and Functional Approaches to Understanding Cancer Aneuploidy (2018, background): “Pub This is an open access article under the CC BY-NC-ND license (http:// aneuploidy and SCNAs have examined copy number based on cytoband (Carter et al., 2006) or based on number of SCNAs, including broad and focal events (Davoli et al., 2017; Buccitelli et al., 2017).”
• Cell cycle, CDKs and cancer: a changing paradigm (2009, background): “Detailed analysis of genes deregulated in chromosomally unstable tumours indicates a high enrichment for centrosomal and mitotic genes in their expression signature”
• Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling (2011, background): “[61] Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z.”
• Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome (2011, background): “These include signatures of stem cells [13–15], aneuploidy [16], wound healing [17,18], hypoxia [19,20], stromal component [21], epithelialmesenchymal transition [22–24]; of mutations in TP53 [25], ALK5 [26]; of loss of PTEN [27]; of perturbations of E2F1 [28], bromodomain 4 [29], mir31 targets [30]”
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. (2007, methodology): “Markers of proliferation and genomic instability have also been measured using microarray profiling analyses.(128,263) While these studies are in early stages and require validation, the current data suggest that these measures may capture more meaningful information than single gene markers of prol”